Langar Global HealthTech ETF

ResMed and Oura Partner to Enhance Sleep Health Education and Care Pathways for US Members

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

FAMAR Group Signs Contract Manufacturing Agreement with GE HealthCare to Expand Iodine Contrast Agent Capacity

Moderna President Stephen Hoge Sells 53,336 Shares at $48.4 and Exercises Options

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Dexcom Announces Launch of Dexcom Flex Continuous Glucose Monitoring System in Germany

Philips Consortium Signs 8-Year Contract with Stockholm for Remote Home Hospital Care

Zimmer Biomet Raises 2026 Buyback and Earnings Forecasts, Stock Rises Short-Term

GEHC Receives 'Hold' Consensus from 17 Brokers, Executives Buy Shares to Show Confidence

Barclay's Analyst Matt Miksic Maintains Sell Rating on Dexcom with $64 Target

Dexcom Investor Day: Focus on G8 New Product, Doubling US CGM Coverage, and International Expansion Strategy

Wall Street Zen Upgrades Intuitive Surgical to Buy; Earnings and Revenue Beat Expectations

Moderna Stock Surges 13% Amid Hantavirus Outbreak; Analysts Cite Limited Commercialization Potential

Dexcom Announces 2030 Targets: 10% Revenue Growth and $10B Buyback

RBC Capital Analyst Maintains Hold Rating on Royal Philips with a Price Target of €25

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

Arbutus Biopharma reports Q1 2026 net income of $169.7 million

Moderna Recognized for mRNA Achievements and Approved for Flu and COVID Combo Vaccine

IQVIA Reports Strong Q1 Earnings and Raises Full-Year Guidance

GE HealthCare to Showcase AI-driven Radiotherapy Tools at ESTRO 2026

Meiwu Tech

Amesite

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Phoenix Asia

Gen Digital - Rights

DOCS

HEAL

LGHT

Doximity (DOCS) fell approximately 25% to an all-time low following disappointing Q4 fiscal 2026 results, leading to a downgrade by KeyBanc Capital Markets. The company's guidance did not meet Wall Street expectations, marking the lowest stock price since its IPO in 2021.

Doximity

First Trust Nasdaq Lux Digital Health Solutions ETF

Global X HealthTech ETF

KeyCorp

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

Doximity hits an all-time low after Q4 results; KeyBanc downgrades

Barclays has downgraded Doximity (NYSE:DOCS) from a 'strong-buy' to a 'hold' rating. Other analysts have also reduced their price targets, with Mizuho lowering it to $26, Goldman Sachs to $24, and BMO to $20. Doximity's stock currently has a consensus rating of 'Hold' and a target price of $30.62. The company has a market cap of $3.50 billion and recently approved a $500 million stock buyback program.

Market Beat

Barclays

Mizuho Financial

Mizuho Financial Group, Inc.

Goldman Sachs

Bank of Montreal

Atlantic Union Bankshares

GS Hldg R

ATLANTIC UNION BANKSHARES CORP 6.875% DEP SH RP 1/400 NON CU PR PF SR A

Atlantic Union Bankshares Corporation

Barclays Downgrades Doximity (NYSE:DOCS) to Hold

Doximity's stock fell in premarket trading after the company reported Q4 2026 earnings that missed expectations, with adjusted EPS at $0.26 versus the $0.28 forecasted. The company cited high AI compute costs impacting margins and projected FY 2027 adjusted EBITDA between $323 million and $335 million, below the $349.5 million expected. Revenue for FY 2027 is anticipated to be between $664 million and $676 million, also below forecasts. CEO Jeffrey A. Tangney emphasized that this year is focused on AI investments despite minimal expected revenue contributions.

Sherwoodnews

iShares Expanded Tech Software Sector ETF

SPDR S&P Software

Factset Research

Doximity sinks on gloomy full-year revenue outlook, says AI compute costs are weighing on margins

Needham & Company LLC has lowered its price target for Doximity (NYSE:DOCS) from $55.00 to $27.00 while maintaining a "buy" rating. This suggests a potential upside of 14.82% from the current price. Other analysts have also adjusted their ratings, with BTIG Research downgrading to "neutral" and JPMorgan reducing their target to $33.00. Doximity's stock opened at $23.52, with a market cap of $4.34 billion. The company has initiated a $500 million share repurchase plan, indicating management's belief in the stock's undervaluation.

JPMorgan Chase

ROYAL BANK OF CANADA

UBS Group AG

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Doximity (NYSE:DOCS) Given New $27.00 Price Target at Needham & Company LLC

Doximity (NYSE:DOCS) reported its Q4 2026 earnings, achieving a record $107 million in free cash flow and $145 million in revenue, a 5% year-on-year increase. The company is investing heavily in AI, with nearly half of US doctors using its tools. Doximity launched an AI monetization strategy targeting pharma clients, viewing it as a long-term multi-billion dollar opportunity. New CFO Matt Sonnefeld and President Dr. Steve Zatz were introduced, with revenue guidance for fiscal 2027 set between $664 to $676 million, anticipating 4% growth at the midpoint and a 49% adjusted EBITDA margin.

benzinga_article

Doximity Q4 2026 Earnings Call Transcript

JPMorgan Chase & Co. has lowered its price target for Doximity (NYSE:DOCS) from $33.00 to $28.00, maintaining a "neutral" rating. This suggests a potential upside of 60.38% from the previous close. Other brokerages have also adjusted their targets, with Robert W. Baird setting a target of $18.00, BMO Capital Markets at $20.00, and Bank of America at $47.00. Doximity's stock traded down to $17.46, with a market cap of $3.22 billion. Insiders have sold shares recently, indicating potential concerns about the stock's valuation.

Defiance Daily Target 2X Long JPM ETF

JPMorgan Chase & Co. Lowers Doximity (NYSE:DOCS) Price Target to $28.00

Doximity, Inc.'s average stock price target has been reduced from $36.74 to $31.11, indicating a potential upside of approximately 33% based on the May 13 closing price. The forecasts from 22 analysts range from $17 to $55 per share. The consensus rating remains a 'Buy' from 25 analysts, with 13 Buys, 12 Holds, and no Sells. This information is sourced from FactSet and does not constitute investment advice.

TradingView

Doximity, Inc. Stock 12‑Month Price Target Cut to $28.11, Implies 20% Upside

Doximity shares fell 24% following disappointing Q4 results, prompting analysts to downgrade ratings and lower price targets. KeyBanc Capital Markets downgraded the stock from Overweight to Sector Weight, citing weak fiscal 2027 growth guidance of 3%-5% and challenges in the pharma ad market. Needham maintained a Buy rating but reduced the price target from $55 to $27, noting revenue growth of 5.1% year-on-year but concerns over decelerating growth. Doximity's stock was trading at $17.70 at the time of the report.

Fidelity

Doximity Sinks 24% As AI Push Fails To Ease Growth Fears

Doximity (DOCS) shares dropped 24% following mixed Q4 results and a weaker FY2027 outlook, prompting analysts to downgrade ratings. Wells Fargo's Stan Berenshteyn lowered the rating to Hold and cut the price target to $18, citing risks in AI competition and rising costs. BTIG's David Larsen also downgraded the stock, highlighting a challenging macro environment and weak pharma demand. Despite the downturn, analysts maintain a Moderate Buy consensus on DOCS, with an average price target of $28.12, suggesting a potential upside of 56.91%.

Tip Ranks

Wells Fargo

Veeva Systems -CL

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Why Is Doximity Stock (DOCS) Falling Today, 5/14/26?

Doximity's shares fell 24% after the company reported weaker-than-expected quarterly profits and issued disappointing fiscal 2027 revenue guidance, raising concerns about slowing growth and increased AI spending. The stock is down over 45% this year as analysts cut price targets, with Needham lowering its target to $27 and Evercore ISI to $19. Doximity's adjusted earnings were 26 cents per share, below expectations, while revenue rose 5% to $145.4 million. The company forecasts first-quarter revenue below Wall Street estimates, indicating potential challenges in monetizing AI investments amid rising competition.

Invezz

Evercore

Doximity plunges 24% on weak guidance, analysts slash PTs on increased AI spending

Langar Global HealthTech ETF(LGHT.US)